Opko buys Israeli biopharma in $480M all-stock deal

Opko Health agreed to purchase Prolor Biotech, an Israel-based biopharmaceutical firm that develops longer-acting versions of approved therapeutic proteins, for around $480 million. "Prolor's drug-product candidates for growth hormone deficiency, hemophilia, obesity and diabetes, along with its broadly applicable technology platforms and efficient research and development center are highly valuable assets that will complement Opkos strategy," Opko Chairman and CEO Phillip Frost said.

View Full Article in:

Globes (Israel) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL